FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284689188> ?p ?o ?g. }

• W4284689188 endingPage "10" @default.
• W4284689188 startingPage "3" @default.
• W4284689188 abstract "Background: Multiple sclerosis (MS) is a disease affecting the central nervous system (CNS), with inflammation and demyelination of nerves, eventually resulting in nerve damage and disabilities. The risk of developing MS enlarged by infectious mononucleosis, which is caused by delayed primary infection by Epstein-Barr Virus (EBV). Early reports consistently demonstrated an increased antibody response in MS patients versus healthy subjects towards different EBV antigens, including the EBV nuclear antigen-1 (EBNA-1). In Iraq, number of researchers found that the EBV have a possible role at some point in the course of the disease, others reported that the EBV pathogenesis have an important role in the triggering of MS disease. Objective: To compare the sero-prevalence of EBV nuclear antigen-1 antibody (EBNA-1 IgG) among the Iraqi MS patients and controls and find out whether there is a relation between disease severity and EBNA-1 IgG titer. Methods: This case-control study conducted on 120 MS patients aged between 13-42 years, and 120 apparently healthy age- and sex-matched volunteers as controls. Three ml of whole blood were collected from all MS patients and controls and put in gel tubes. The blood samples were centrifuged at 5000 RPM for 5 minutes to get serum from the gel tubes. Serum was preserved in (-20ºC), and then used for enzyme-linked immunosorbent assay (ELISA). The ELISA study was performed using ELISAs kits (Abnova /Taiwan) for EBNA-1 IgG antibodies measurement. Results: EBNA-1 IgG was positive in 51.7% (62/120) of MS patients and 39.2% (47/120) of controls, (P=0.035). The median of EBNA-1 IgG level of MS patients and controls were 81.08 U/ml, and 67.73 U/ml, respectively (P=0.043). And EBNA-1IgG was significantly higher in younger age groups. Patients with the first-line and second-line treatment showed no significant differences in EBNA-1 IgG levels, while the median level in patients without treatment (newly diagnosed) and those who were at early years of the disease was higher. Conclusion: EBNA-1 antibody could play a triggering role in MS because it is significantly higher in MS patients than in controls, especially at younger age groups, early stages of the disease and in female patients. Keywords: Multiple sclerosis, EBV, EBNA-1 IgG, ELISA Citation: Ali ZA, Al-Obaidi AB, Almashta SA. The potential role of Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1) in multiple sclerosis. Iraqi JMS. 2022; 20(1): 3-10. doi: 10.22578/IJMS.20.1.2" @default.
• W4284689188 created "2022-07-08" @default.
• W4284689188 creator A5016612684 @default.
• W4284689188 creator A5018139546 @default.
• W4284689188 creator A5064204070 @default.
• W4284689188 date "2022-06-30" @default.
• W4284689188 modified "2023-09-30" @default.
• W4284689188 title "THE POTENTIAL ROLE OF EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN-1 (EBNA-1) IN MULTIPLE SCLEROSIS" @default.
• W4284689188 doi "https://doi.org/10.22578/ijms.20.1.2" @default.
• W4284689188 hasPublicationYear "2022" @default.
• W4284689188 type Work @default.
• W4284689188 citedByCount "0" @default.
• W4284689188 crossrefType "journal-article" @default.
• W4284689188 hasAuthorship W4284689188A5016612684 @default.
• W4284689188 hasAuthorship W4284689188A5018139546 @default.
• W4284689188 hasAuthorship W4284689188A5064204070 @default.
• W4284689188 hasBestOaLocation W42846891881 @default.
• W4284689188 hasConcept C142724271 @default.
• W4284689188 hasConcept C147483822 @default.
• W4284689188 hasConcept C159654299 @default.
• W4284689188 hasConcept C203014093 @default.
• W4284689188 hasConcept C2522874641 @default.
• W4284689188 hasConcept C2776129502 @default.
• W4284689188 hasConcept C2779134260 @default.
• W4284689188 hasConcept C2780494569 @default.
• W4284689188 hasConcept C2780640218 @default.
• W4284689188 hasConcept C2780942790 @default.
• W4284689188 hasConcept C2781028063 @default.
• W4284689188 hasConcept C2781375147 @default.
• W4284689188 hasConcept C32611913 @default.
• W4284689188 hasConcept C71924100 @default.
• W4284689188 hasConceptScore W4284689188C142724271 @default.
• W4284689188 hasConceptScore W4284689188C147483822 @default.
• W4284689188 hasConceptScore W4284689188C159654299 @default.
• W4284689188 hasConceptScore W4284689188C203014093 @default.
• W4284689188 hasConceptScore W4284689188C2522874641 @default.
• W4284689188 hasConceptScore W4284689188C2776129502 @default.
• W4284689188 hasConceptScore W4284689188C2779134260 @default.
• W4284689188 hasConceptScore W4284689188C2780494569 @default.
• W4284689188 hasConceptScore W4284689188C2780640218 @default.
• W4284689188 hasConceptScore W4284689188C2780942790 @default.
• W4284689188 hasConceptScore W4284689188C2781028063 @default.
• W4284689188 hasConceptScore W4284689188C2781375147 @default.
• W4284689188 hasConceptScore W4284689188C32611913 @default.
• W4284689188 hasConceptScore W4284689188C71924100 @default.
• W4284689188 hasIssue "1" @default.
• W4284689188 hasLocation W42846891881 @default.
• W4284689188 hasLocation W42846891882 @default.
• W4284689188 hasOpenAccess W4284689188 @default.
• W4284689188 hasPrimaryLocation W42846891881 @default.
• W4284689188 hasRelatedWork W1529180498 @default.
• W4284689188 hasRelatedWork W2025227319 @default.
• W4284689188 hasRelatedWork W2030238129 @default.
• W4284689188 hasRelatedWork W2128356179 @default.
• W4284689188 hasRelatedWork W2144726140 @default.
• W4284689188 hasRelatedWork W2155411646 @default.
• W4284689188 hasRelatedWork W2346618318 @default.
• W4284689188 hasRelatedWork W2400528911 @default.
• W4284689188 hasRelatedWork W3012791892 @default.
• W4284689188 hasRelatedWork W4319662009 @default.
• W4284689188 hasVolume "20" @default.
• W4284689188 isParatext "false" @default.
• W4284689188 isRetracted "false" @default.
• W4284689188 workType "article" @default.